XORTX Therapeutics Inc. submitted a FORM 6-K reporting financial results for the six months ending June 30, 2025, and confirmed filing under Form 20-F on August 14, 2025. The filing includes interim financial statements and management discussions, reflecting ongoing updates in compliance with U.S. securities regulations.